Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
ORAMED PHARMACEUTICALS INC. (ORMP)
|
Add to portfolio |
|
|
|
| Price: |
$9.32
| | Metrics |
| OS: |
40.3
|
M
| |
13
|
% ROE
|
| Market cap: |
$375
|
M
| |
-18
|
% ROIC
|
|
Net cash:
|
$12.2
|
M
| |
$0.30
|
per share
|
|
EV:
|
$363
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($26.8)
|
M
| |
|
|
|
EBIT
|
($26.9)
|
M
| |
|
|
| EPS |
$0.51
| |
18.1
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Aug-31-21 | Aug-31-20 | Aug-31-19 | Aug-31-18 | Aug-31-17 | Aug-31-16 | Aug-31-15 |
| Revenues | 2.7 | 2.7 | 2.7 | 2.7 | 2.4 | 2.5 | 0.6 | 0.0 |
| Revenue growth | | -0.3% | 0.3% | 10.4% | -0.3% | 283.2% | | -100.0% |
| Cost of goods sold | -0.3 | 0.0 | 0.0 | 0.1 | -0.1 | 0.2 | 0.5 | 0.0 |
| Gross profit | 3.0 | 2.7 | 2.7 | 2.6 | 2.5 | 2.3 | 0.2 | 0.0 |
| Gross margin | 109.8% | 100.0% | 100.0% | 96.7% | 103.5% | 92.4% | 23.6% | |
| Selling, general and administrative | 15.7 | | | | | | | |
| Sales and marketing | 1.9 | | | | | | | |
| Research and development | 27.6 | 21.0 | 10.2 | 13.5 | 12.0 | 10.3 | 7.7 | 4.8 |
| General and administrative | | 5.9 | 4.2 | 3.7 | 4.1 | 2.8 | 2.5 | 2.6 |
| EBIT | -40.6 | -24.2 | -11.8 | -14.6 | -13.5 | -10.8 | -10.0 | -7.4 |
| EBIT margin | -1502.0% | -896.2% | -433.8% | -541.3% | -552.3% | -438.6% | -1561.6% | |
| Pre-tax income | 37.8 | 23.0 | 11.5 | 14.1 | 12.7 | 10.1 | 9.6 | 7.2 |
| Income taxes | 0.1 | 0.0 | 0.0 | -0.3 | 0.0 | -0.4 | -1.3 | 0.0 |
| Tax rate | 0.3% | 0.0% | 0.0% | | 0.0% | | | 0.0% |
| Net income | 36.6 | 23.0 | 11.5 | 14.4 | 12.7 | 10.5 | 11.0 | 7.2 |
| Net margin | 1352.6% | 850.5% | 424.8% | 531.1% | 519.7% | 426.7% | 1710.5% | |
| |
| Diluted EPS | $0.94 | $0.81 | $0.56 | $0.82 | $0.86 | $0.79 | $0.87 | $0.67 |
| Shares outstanding (diluted) | 39.0 | 28.5 | 20.5 | 17.5 | 14.9 | 13.3 | 12.6 | 10.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|